Literature DB >> 11928075

Hepatic vein thrombosis (Budd-Chiari syndrome).

Dominique-Charles Valla1.   

Abstract

Hepatic vein thrombosis is caused by one or several thrombogenic conditions, of which myeloproliferative disorders are the most frequent. Thrombosis and its fibrous sequelae can affect the veins diffusely or locally. Severity is determined by the extent and velocity of the thrombotic process. Development of venous collateral vessels is an important compensatory mechanism. Some patients can be totally free of symptoms. Major complications are intractable ascites, liver insufficiency, and gastrointestinal bleeding. Diagnosis can be made via ultrasonography or magnetic resonance imaging in a majority of cases. The main prognostic factors are age, Child-Pugh score, and response of ascites to diuretics. Medical therapy includes control of causal factors, anticoagulation, and nonspecific treatment of complications. Procedures aiming to restore outflow of hepatic blood are indicated in patients with uncontrolled manifestations. Percutaneous angioplasty, followed by portosystemic shunt (including a transjugular intrahepatic portosystemic stent shunt) and eventually liver transplantation can be proposed in a graded manner. The current 10-year survival rate is about 75%.

Entities:  

Mesh:

Year:  2002        PMID: 11928075     DOI: 10.1055/s-2002-23202

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  21 in total

1.  Budd-Chiari syndrome with portal, splenic, and superior mesenteric vein thrombosis treated with TIPS: who dares wins.

Authors:  A Mancuso; A Watkinson; J Tibballs; D Patch; A K Burroughs
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

2.  Etiology and portal vein thrombosis in Budd-Chiari syndrome.

Authors:  Oguz Uskudar; Meral Akdogan; Nurgul Sasmaz; Sevinc Yilmaz; Muharrem Tola; Burhan Sahin
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

3.  Prevalence of portal vein thrombosis in Egyptian patients with Budd-Chiari syndrome.

Authors:  Mohammed Amin Sakr; Nadia Abdelkader; Hany Dabbous; Ahmed Eldorry
Journal:  Indian J Gastroenterol       Date:  2014-06-15

Review 4.  Noncirrhotic portal hypertension.

Authors:  Harshal Rajekar; Rakesh K Vasishta; Yogesh K Chawla; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 5.  Cross-sectional imaging of acute abdominal conditions in the oncologic patient.

Authors:  Matthew T Heller; Vineet Khanna
Journal:  Emerg Radiol       Date:  2011-06-24

6.  Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study.

Authors:  Mohammad Sakr; Eman Barakat; Sara Abdelhakam; Hany Dabbous; Said Yousuf; Mohamed Shaker; Ahmed Eldorry
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

7.  Rapid development of a hepatocellular carcinoma in isolated thrombosis of hepatic veins (classic Budd-Chiari syndrome): case report and review of literature.

Authors:  Jens Walldorf; Andrea Tannapfel; Hans Jürgen Holzhausen; Christian Wittekind; Thomas Seufferlein; Utz Settmacher; Wolfgang E Fleig; Matthias M Dollinger
Journal:  BMJ Case Rep       Date:  2009-11-29

8.  Budd-Chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt.

Authors:  Alexandra Zahn; Daniel Gotthardt; Karl Heinz Weiss; Götz Richter; Jan Schmidt; Wolfgang Stremmel; Peter Sauer
Journal:  BMC Gastroenterol       Date:  2010-03-01       Impact factor: 3.067

9.  JAK2V617F mutation in patients with splanchnic vein thrombosis.

Authors:  Sandra Guerra Xavier; Telma Gadelha; Glicínia Pimenta; Angela Maria Eugenio; Daniel Dias Ribeiro; Fernanda Mendes Gomes; Martin Bonamino; Ilana Renault Zalcberg; Nelson Spector
Journal:  Dig Dis Sci       Date:  2009-08-19       Impact factor: 3.199

Review 10.  Hepatic venous outflow obstruction: three similar syndromes.

Authors:  Ulas-Darda Bayraktar; Soley Seren; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.